McCormick & Company (MKC)
NYSEConsumer StaplesPackaged FoodsSnapshot 2026-07-07
$52.22+0.85%
Close 2026-07-07 · 1-day change
Reading MKC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MKC free→NYSEConsumer StaplesPackaged FoodsSnapshot 2026-07-07
Reading MKC? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MKC free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on steady growth. The current thesis state is intact, as recent performance remains strong within its industry, although management execution has shown volatility.
The market seems to have priced in a low level of fragility, reflecting a justified valuation. MKC is currently viewed as cheap compared to its peers, with expectations slightly negative, indicating that the market may not fully account for potential upside.
Fundamentals are likely to show modest organic sales growth, driven by volume and pricing strategies. The company is on track with margin expansion through its CCI program, although management's integration of the Unilever Foods business has had mixed results.
The long-term thesis hinges on the performance of sector bellwethers like KHC, GIS, and HRL, as their results will impact MKC's momentum. Additionally, the company's ability to execute on its management priorities will be crucial for maintaining growth and margin expansion.
In summary, MKC's outlook remains stable, but it faces risks from sector performance and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports organic sales growth. However, there are ongoing struggles with financing for the Unilever transaction.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This would show McCormick is improving its ability to drive sales without acquisitions. Strong organic growth is key for long-term health.
Confirms:Q2 organic sales growth is over 3%.
Disproves:Q2 organic sales growth is under 1%.
Why it matters: Earnings per share below expectations may show profit problems and hurt investor trust.
Confirms:Q2 earnings per share reported below $3.05.
Disproves:Q2 earnings per share reported above $3.13.
Why it matters: Lower operating income growth may mean rising costs and problems with profits.
Confirms:Operating income growth was below 16%.
Disproves:Operating income growth was above 20%.
Why it matters: Strong results from McCormick de Mexico can support the acquisition plan and boost growth.
Confirms:Management says McCormick de Mexico adds more than 13% to total sales growth.
Disproves:McCormick de Mexico's share is less than 11% of total sales growth.
Why it matters: Better margins show good cost management and pricing power. This shows the company can stay profitable.
Confirms:Gross profit margin reported above 38.6% for Q2 2026.
Disproves:Gross profit margin reported below 37.8% for Q2 2026.
Why it matters: A higher operating income margin shows better cost control. This is key for growth.
Confirms:Q2 operating income margin is more than 14%.
Disproves:Q2 operating income margin is less than 12%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.